FDA clears Abbott next-gen glucose monitor for young children

The FDA has issued 510(k) clearance for Abbott’s (NYSE:ABT) FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system for patients as young as four years old with diabetes.

The company says the device is the only iCGM system with optional real-time alarms that measure glucose levels every minute over a period of 14 days (wear time).

https://seekingalpha.com/news/3582909-fda-clears-abbott-next-gen-glucose-monitor-for-young-children